Chandra Bhagat Pharma Ltd

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of May 30, 2025, Chandra Bhagat's valuation has been downgraded to risky due to overvaluation, with a PE ratio of 42.25 and an EV to EBITDA of -36.70, significantly underperforming its peers and the market.

As of March 2021, the management team of Chandra Bhagat includes Hemant C Bhagat (Chairman & Managing Director), Pranav H Bhagat (Whole-time Director), Prachi Pranav Bhagat (Director & CFO), Ravindra Gajanan Awati (Independent Director), and Abha Praveen Doshi (Independent Director). They are responsible for the company's governance and strategic direction.

Chandra Bhagat Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2003 and converted to a Public Limited Company in 2019. It currently has no reported sales or profit data, with a market cap of Rs 46 Cr and a P/E ratio of 42.00.

Chandra Bhagat's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Chandra Bhagat has below average performance with a 1-year return of -42.15%.

As of 05-Jun, Chandra Bhagat Pharma Ltd's stock price is Rs 56.00, down 8.94% and significantly underperforming its sector. The stock has declined 15.15% year-to-date and 46.64% over the past year, despite a notable increase in investor participation.